Titan Biotech (BOM:524717) Marketable Securities: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524717 Titan Biotech Ltd BOM:524717
51 GF Score
Price ₹414.85
GF Value ₹162.39
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Titan Biotech Marketable Securities?

Titan Biotech BOM:524717 +5.00% 51 Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:524717 with a GF Score™ of 51/100 and a GF Value™ of ₹162.39 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Titan Biotech's Marketable Securities for the quarter that ended in Jun. 2026 was ₹0 Mil.

Titan Biotech's annual Marketable Securities stayed the same from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹0 Mil) but then increased from Mar. 2025 (₹0 Mil) to Mar. 2026 (₹4 Mil).

Titan Biotech  (BOM:524717) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Titan Biotech Marketable Securities Related Terms

Titan Biotech Marketable Securities Historical Data

* Premium members only.

The historical data trend for Titan Biotech's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Titan Biotech Marketable Securities Chart

Titan Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.96

Titan Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 19.66 0.00 3.96 0.00
BOM:524717
51GF Score
Titan Biotech Ltd BOM:524717
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Titan Biotech Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹0 Mil mean?
Titan Biotech (BOM:524717) has a Marketable Securities of ₹0 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Titan Biotech and its competitors.
Is Titan Biotech's Marketable Securities too high?
Titan Biotech's current Marketable Securities is ₹0 Mil. Overall, Titan Biotech has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Marketable Securities compare to VRTX and REGN?
Titan Biotech's Marketable Securities of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Titan Biotech and its competitors. Titan Biotech's current Marketable Securities is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹162.39, compared to a current price of ₹414.85 — trading 155.5% above its estimated fair value. The current Marketable Securities is ₹0 Mil. Titan Biotech's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Marketable Securities is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Titan Biotech (BOM:524717) Overvalued in 2026?

Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued. The current stock price of ₹414.85 is trading 155.5% above its estimated GF Value™ of ₹162.39. GuruFocus considers Titan Biotech to be Significantly Overvalued.

Key valuation signals for BOM:524717:

  • Marketable Securities: ₹0 Mil
  • GF Value™: ₹162.39 vs. price of ₹414.85 (155.5% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Titan Biotech Business Description

Address Netaji Subhash Place, 903-909, 9th Floor, Bigjos Tower, New Delhi, IND, 110034
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
51GF Score

Get the complete analysis for BOM:524717

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹414.85
Price
₹162.39
GF Value